证券代码：300143 证券简称：星普医科 广东星普医学科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Group 1: Proton Therapy System - The Protom Radiance 330 proton therapy system is the most advanced compact proton therapy system globally, integrating modularity and customization, which effectively reduces the cost of tumor radiotherapy [2] - The company aims to promote and sell the Protom system both domestically and internationally due to its advantages in size, modularity, and precision [2] Group 2: Hospital Management and Expansion - The company has a specialized management team for hospital operations, covering the entire process from industry research to initial setup and management [2] - In 2015, the company began transitioning into the medical services sector, successfully acquiring two hospitals in 2017: Hangzhou Zhongwei and Sichuan Friendship [2] - Plans are underway to establish new hospitals with a focus on radiation therapy in cities like Changsha and Changchun, with additional new hospitals expected to open this year [2][3] Group 3: Investment and Returns - The board has approved an investment budget of 500 million yuan for establishing new hospitals [3] - The average investment return period for hospitals is approximately five years, with expectations for new hospitals to achieve profitability within one year of opening [3] Group 4: Market Opportunities and Growth - The company is increasing its sales efforts in overseas markets while the domestic market for radiation therapy is experiencing a supply-demand imbalance due to the gradual closure of military hospitals [3] - The company is seizing the opportunity to capture market share and attract experienced medical personnel [3] Group 5: Product Advantages - The company's gamma knife products are competitively priced at about 75% of foreign counterparts, benefiting from unique technological advantages that reduce costs while maintaining efficacy [4] - The construction period for a proton therapy center typically ranges from 12 to 18 months [4]

证券代码：300143 证券简称：星普医科 广东星普医学科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------------------|-----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 活动类别 | □ \n□ \n□ 现场参观 \n□ 中泰证券 江琦、谢木青 | 特定对象调研 □分析师会议 \n媒体采访 □业绩说明会 \n□新闻发布会 ■路演活动 ...

Financial Performance - The company's Q3 2020 revenue reached CNY 204.48 million, a year-on-year increase of 38.78% [2] - Year-to-date revenue as of the report date was CNY 487.86 million, up 21.37% year-on-year [2] - Q3 net profit attributable to shareholders was CNY 15.60 million, a 1.12% increase year-on-year; year-to-date net profit was CNY 42.53 million, up 8.94% [2] Business Segments Medical Equipment Segment - The medical equipment segment reported a revenue growth of 70% in Q3 [3] - The company is focusing on high-end, digital, and networked strategies to establish a leading global tumor treatment technology brand [3] Medical Services Segment - The medical services segment achieved a revenue of CNY 129.67 million in Q3, reflecting a 26% year-on-year growth [6] - The company is enhancing quality control and operational capabilities in hospitals, with a focus on integrating online and offline services [4] Strategic Initiatives - The company is investing in R&D, with total R&D expenses for the first three quarters of 2020 amounting to CNY 11.68 million, a 249% increase year-on-year [7] - The introduction of new treatment technologies, such as PET-CT and TOMO, is aimed at improving patient care and expanding service offerings [5] Market Positioning - The company aims to build a comprehensive tumor treatment ecosystem, integrating screening, surgery, treatment, rehabilitation, and care [9] - The tumor business accounted for 33% of the hospital segment's revenue in the first three quarters of 2020 [12] Challenges and Future Outlook - Profit margins have decreased due to increased costs related to pandemic response and hospital accreditation processes [6][7] - The company plans to optimize management and enhance bed utilization rates to improve profitability [7] - The successful accreditation of Sichuan Friendship Hospital as a Class III hospital is expected to enhance the company's brand and operational capabilities [10]

证券代码：300143 证券简称：星普医科 广东星普医学科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300143 证券简称：星普医科 广东星普医学科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类 \n别 | □ □现场参观 | ■特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n新闻发布会 □路演活动 | | 参与单位名称及人 | □ | 其他 （请文字说明其他活动内容） 广发证券 杨正；中泰证券 谢木青；信达证券 孟阳；玖石投资 杨洋 | | 员姓名 | ...

证券代码：300143 证券简称：星普医科 广东星普医学科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------------|--------------------------|--------------------------------------------------------| | | | ■特定对象调研 □分析师会议 | | 投资者关系活 | □媒体采访 □业绩说明会 | | | 动类别 | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 天风证券 王金成；中信证券 孙晓晖、魏文娅、季向昆 | | 及人员姓名 | | | | 时间 | 2018 年 3 月 30 | 日 | | 地点 | 成都市高新区天府大道北段 | 1199 号星玛康会议室 | | 上市公司 | | 董事长兼总经理：霍昌英；副董事长：徐涛； | | 接待人员姓名 | | 董事会秘书：赵璐； 证券事务代表：刘杰 | | 投资者关系活 动主要内容介 | 一、公司基本 ...

Group 1: Hospital Overview - Friendship Hospital has a total building area of over 50,000 square meters and 1,200 beds, with 600 currently open [2] - The hospital is equipped with advanced medical facilities, including the latest PET-CT and GE cardiovascular imaging systems [2] - It has over 40 clinical departments, with key specialties in oncology, radiotherapy, and neurosurgery [3] Group 2: Management and Quality - The hospital employs a comprehensive quality management model, achieving the highest patient satisfaction in a recent evaluation [4] - The management team is described as pragmatic and innovative, with a strong focus on medical quality and safety [4] Group 3: Future Plans - The hospital aims to achieve "three A" status and expand its specialties to include pediatrics, hematology, and rehabilitation within three years [4] - Plans are in place to gradually increase the number of open beds based on departmental development [5] Group 4: Patient Demographics and Referrals - Approximately 600 outpatients visit the hospital daily, with two-thirds from Chengdu and one-third from outside the city [7] - The hospital receives referrals from Sichuan Provincial People's Hospital, primarily for post-operative rehabilitation [6] Group 5: Financial Performance - In 2017, the hospital's revenue was 260 million yuan, with a net profit of over 80 million yuan [8] - The hospital expects a growth rate of 10% to 20% in oncology treatment numbers this year [8] Group 6: Equipment and Treatment Capacity - The hospital is equipped with advanced radiotherapy systems, treating approximately 100-140 patients monthly with the head gamma knife [8] - The average length of stay for oncology patients undergoing radiotherapy is 6-7 weeks [14] Group 7: Market Position and Strategy - The hospital is positioned as a leading private healthcare provider in the region, focusing on oncology services [10] - The company plans to establish 30 hospitals by 2020, expanding its influence in the healthcare market [10] Group 8: Challenges and Opportunities - The hospital faces market pressure as public perception of private hospitals remains a challenge [19] - There is a growing trend of patients choosing private hospitals for better service and reasonable pricing [19]

证券代码：300143 证券简称：盈康生命 盈康生命科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ | 其他 （以电话会议形式参加华泰证券 2021 年度投资峰 | | | 会） | | | 参与单位名称及 | 以电话会议形式参加华泰证券 | 2021 年度投资峰会，投资者 | | 人员姓名 | | 名单由华泰证券提供，包括嘉实基金管理有限公司、万家基金 | | | | 管理有限公司、国寿安保基金、上海益昶资产管理有限公司、 | | | | 朱雀基金、银河基金、建信保险、中海基金、醇厚基金、中信产 | | | | 业基金、上海兴聚投资管理有限公司、上 ...

证券代码：300143 证券简称：盈康生命 盈康生命科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------|------------------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | £ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | R 其他 （电话会议） | | | 参与单位名称及 | | 本次电话会议由华泰证券组织召开，投资者名单由华泰证券 | | 人员姓名 | | 提供，包括嘉实基金管理有限公司、诺安基金、汇添富基金、 | | | | 中银基金、工银瑞信基金、睿远基金、泰康资产、大成基金、华 | | | | 夏基金、中信证券、中泰证券、东方证券、寻常资产、申九资产、 | | | | 南土资产、于翼资产、睿亿投资等三十余名机构投资者。 | | 时间 | 2020 年 12 月 24 ...